Cipla Gets ESG Rating of 68 from Niche
Cipla Ltd received an ESG rating of 68 from Niche, a SEBI-registered provider. The rating was communicated to NSE and BSE, with Cipla notified via a BSE alert. Source: BSE
Stock news timeline · CIPLA
Cipla
News timeline · Last 30 days
23 Aug 2026 – 21 Sep 2026 · Times in IST
- Timeline updates
- 27
- Bullish
- 12
- Neutral
- 14
- Bearish
- 1
- Active days
- 12
News timeline
Showing 27 of 27 updates · Newest first
No matching updates
Change the keyword or sentiment above, then click Apply.
Friday, 18 Sep 20261 update
Friday, 11 Sep 20262 updates
Macquarie Keeps Cipla 'Outperform'; Sets ₹1,675 Target Despite FDA Concerns
Macquarie maintains Outperform on Cipla with ₹1,675 target, citing limited near-term earnings impact despite FDA compliance concerns. Key risks include microbial contamination and adverse environmental conditions; robust remediation and CAPA evidence required. Source: Livesquawk
Cipla: Macquarie on Cipla Outperform, Target Price ₹1,675, as key observations from the Pithampur plant’s previous inspection regarding Field Alert Report submission appear addressed, though five repeat observations remain; near-term earnings impact is expected to be limited, but microbial contamination and adverse environmental conditions are critical compliance concerns requiring robust remediation and substantial CAPA evidence to satisfy the FDA.
Friday, 04 Sep 20262 updates
Cipla: Morgan Stanley on Cipla Maintains Underweight with Target Price of ₹1,218 as the Qilu partnership for US commercialization of the Keytruda biosimilar strengthens Cipla’s oncology/biosimilars portfolio and specialty strategy, though competition remains high with at least 13 pembrolizumab biosimilars in development.
Morgan Stanley Sets Cipla Target at ₹1,218, Rates 'Underweight'
Morgan Stanley rates Cipla underweight with a target price of ₹1,218. Cipla leads US commercialization; Qilu handles development and regulatory filings. Source: ScoutQuest
Thursday, 03 Sep 20263 updates
CIPLA: Subsidiary InvaGen Pharmaceuticals Enters Exclusive Deal With Qilu Pharmaceutical For Keytruda Biosimilar QL2107
Cipla to Supply Keytruda Biosimilar in US with Qilu Partnership
Cipla partners with Qilu Pharmaceutical to license and supply biosimilar to Keytruda (Pembrolizumab) for the US market. Cipla will commercialize QL2107 in the US, leveraging its oncology-focused portfolio and strong presence. Source: BSE
Cipla Amalgamation Gets NCLT Nod, Waives Shareholder Meetings
Cipla Ltd notifies shareholders and creditors about an amalgamation approval process. NCLT waives meetings for shareholders and unsecured creditors; no secured creditors involved. Source: ScoutQuest
Tuesday, 01 Sep 20261 update
Cipla Rises 0.8% on Cancer Drug Deal; Q1 Profit Falls 39% to ₹789 Cr
Cipla gains 0.8% after licensing Sino Biopharma's cancer drug TQB2102 for India, South Africa, and 5 markets. Cipla's Q1 net profit fell 39% YoY to ₹789 cr; revenue rose 2% to ₹7,119 cr, missing estimates. Source: CNBC TV 18
Monday, 31 Aug 20263 updates
Cipla Secures Exclusive Rights for HER2 Cancer Drug in Key Markets
Cipla gains exclusive rights for TQB2102, a HER2 bispecific ADC cancer drug. Rights cover India, South Africa, 5 emerging markets; promising for HER2-low breast cancer. Source: ScoutQuest
Cipla: Co. Enters Exclusive Licensing Deal With SBP Group For HER2 Bispecific ADC Rolditamig Deuderuxtecan (TQB2102); Deal Includes India, South Africa, And Five Other Emerging Markets; Cipla Will Manage Local Development And Sales.
Cipla's InvaGen Gets USFDA VAI Nod
USFDA classifies Cipla's US subsidiary InvaGen inspection as Voluntary Action Indicated (VAI). This VAI classification highlights observations without formal enforcement, as disclosed to BSE, NSE, and Luxembourg Stock Exchange. Source: Financial Express
Sunday, 30 Aug 20261 update
Maharashtra FDA Reverses Cipla Licence Cancelation After HC Criticism
Maharashtra FDA withdrew its order to cancel Cipla Pharma's drug sale licence in Pune. Bombay HC criticized the FDA for high-handed actions against Cipla Pharma Life Sciences Ltd. Source: The Hindu BusinessLine
Saturday, 29 Aug 20261 update
Cipla: USFDA Classifies InvaGen Pharmaceuticals Inc.'s Unit 3 Inspection In New York As Voluntary Action Indicated (VAI)
Friday, 28 Aug 20262 updates
Cipla's Pune Licences Cancelled by FDA Over Storage & Claims Issues
Cipla's Pune drug sales licences were cancelled by Maharashtra FDA due to storage deficiencies, stock discrepancies, and illegal promotional claims. FDA cited risks from misleading claims, improper storage, and incomplete recall compliance of Reactin Plus, a Schedule H drug. Source: NDTV Profit
Cipla's InvaGen Facility Gets VAI Nod from USFDA, Minor Issues Noted
USFDA inspected Cipla's InvaGen facility in NY from 13-17 July 2026. Inspection classified as VAI on 28 Aug 2026, indicating minor issues. Source: ScoutQuest
Thursday, 27 Aug 20262 updates
Cipla Gains Full Control of Aspergen Inc After Restructuring
Cipla completes restructuring, gaining full control of Aspergen Inc. via Aspergen Limited. Source: Livesquawk
Cipla: Company Finalizes Restructuring With Aspergen Limited Taking Full Control Of Aspergen Inc.
Wednesday, 26 Aug 20266 updates
Cipla Allots 5,281 Shares; Paid-Up Capital Now ₹1615 Cr
Cipla Ltd. has allotted 5,281 equity shares under ESOS 2013-A & ESAR Scheme 2021. Post allotment, Cipla's paid-up share capital increased to INR 1,61,57,16,894. Source: BSE
Cipla Gets 7 USFDA Observations; Citi Stays 'Buy' with ₹1,700 Target
Cipla's Pithampur plant received 7 USFDA observations; Citi maintains 'Buy' with ₹1,700 target. Citi expects no near-term earnings impact; Pithampur resolution could aid respiratory product supplies. Source: CNBC TV 18
Cipla Falls on USFDA Alert; Citi Retains ₹1,700 Target
Cipla shares drop after USFDA observations; Citi sees no earnings impact. Citi maintains a target price of ₹1,700 for Cipla. Source: ScoutQuest
Honasa Drops Fluence Deal; Varun Beverages Eyes RTD Alcohol Subsidiary
Honasa cancels Fluence Pharma deal; Varun Beverages plans RTD alcohol subsidiary. Welspun stake sale, Tata Motors 5G tie-up, Cipla FDA issues, HEG demerger, Ather funding. Source: The Hindu Business Line
Citi Keeps Buy on Cipla, Sets ₹1,700 Target Despite USFDA Observations
Citi maintains Buy on Cipla with a ₹1,700 target; Pithampur gets 7 USFDA observations. Near-term earnings unlikely affected; resolution may boost respiratory product supply flexibility. Source: Livesquawk
Cipla: Citi on Cipla Maintains Buy with Target Price of ₹1,700 as Pithampur received seven USFDA observations, but near- to medium-term earnings are unlikely to be affected due to key approvals being linked to Goa and US facilities, while eventual resolution would improve supply flexibility for respiratory products.
Tuesday, 25 Aug 20263 updates
Cipla: Co. Gets Form 483 With 7 Observations After USFDA Follow-Up Visit To Pithampur Facility.
Cipla: Company Gets Form 483 With Seven Comments After USFDA Follow-Up Visit To Pithampur Facility
Cipla Gets 7 USFDA Observations; Vows Timely Fix
USFDA conducted cGMP inspection at Cipla's Pithampur facility, noting 7 observations. Cipla committed to addressing all observations within the given timeline. Source: ScoutQuest